The launch and diffusion of new patented medicines by therapeutic value
Clicks: 3
ID: 313388
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #37 of 98 articles by views in Health Affairs Scholar
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction Evidence on the launch and diffusion of therapeutically important new medicines is limited. We examined the launch and diffusion of new patented medicines in 14 countries by therapeutic value. Methods We analyzed IQVIA MIDAS® quarterly sales data for 422 patented molecules first launched between 2013-2021 in any of 14 countries (Australia, Belgium, Canada, France, Germany, Italy, Japan, the Netherlands, Norway, Spain, Sweden, Switzerland, the United Kingdom, and the United States) and followed them for at least two years. Therapeutic value for each molecule was obtained from rating agencies in Canada, Germany, France, and the United States. Results Our main time-to-launch analysis showed that, compared with molecules offering major incremental benefit, those with moderate benefit were launched more quickly in several countries, including Canada, France, the Netherlands, Norway, Sweden, and the United Kingdom. Molecules with little to no benefit were launched even more rapidly in the Netherlands. However, once launched, market share by volume did not change significantly over the first five years regardless of therapeutic value level in each country. Conclusion New patented medicines with major incremental therapeutic benefit might not always be launched faster than other medicines. Strategies to balance pricing with adoption and diffusion warrant further investigation.
| Reference Key |
openalex_W7161414316
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Wei Zhang, Daphne Guh, Alexander C T Tam, Paul Grootendorst, Aidan Hollis, Aslam H. Anis |
| Journal | Health Affairs Scholar |
| Year | 2026 |
| DOI |
10.1093/haschl/qxag119
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.